177 related articles for article (PubMed ID: 33016563)
1. High-grade serous peritoneal cancer follows a high stromal response signature and shows worse outcome than ovarian cancer.
Jacob F; Marchetti RL; Kind AB; Russell K; Schoetzau A; Heinzelmann-Schwarz VA
Mol Oncol; 2021 Jan; 15(1):91-103. PubMed ID: 33016563
[TBL] [Abstract][Full Text] [Related]
2. Tissue glycomics distinguish tumour sites in women with advanced serous adenocarcinoma.
Anugraham M; Jacob F; Everest-Dass AV; Schoetzau A; Nixdorf S; Hacker NF; Fink D; Heinzelmann-Schwarz V; Packer NH
Mol Oncol; 2017 Nov; 11(11):1595-1615. PubMed ID: 28853212
[TBL] [Abstract][Full Text] [Related]
3. Connective tissue growth factor as a novel therapeutic target in high grade serous ovarian cancer.
Moran-Jones K; Gloss BS; Murali R; Chang DK; Colvin EK; Jones MD; Yuen S; Howell VM; Brown LM; Wong CW; Spong SM; Scarlett CJ; Hacker NF; Ghosh S; Mok SC; Birrer MJ; Samimi G
Oncotarget; 2015 Dec; 6(42):44551-62. PubMed ID: 26575166
[TBL] [Abstract][Full Text] [Related]
4. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG).
Dahm-Kähler P; Borgfeldt C; Holmberg E; Staf C; Falconer H; Bjurberg M; Kjölhede P; Rosenberg P; Stålberg K; Högberg T; Åvall-Lundqvist E
Gynecol Oncol; 2017 Jan; 144(1):167-173. PubMed ID: 27817932
[TBL] [Abstract][Full Text] [Related]
5. High-grade serous tubo-ovarian cancer refined with single-cell RNA sequencing: specific cell subtypes influence survival and determine molecular subtype classification.
Olbrecht S; Busschaert P; Qian J; Vanderstichele A; Loverix L; Van Gorp T; Van Nieuwenhuysen E; Han S; Van den Broeck A; Coosemans A; Van Rompuy AS; Lambrechts D; Vergote I
Genome Med; 2021 Jul; 13(1):111. PubMed ID: 34238352
[TBL] [Abstract][Full Text] [Related]
6. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
7. International Federation of gynecology and obstetrics staging classification for cancer of the ovary, fallopian tube, and peritoneum: estimation of survival in patients with node-positive epithelial ovarian cancer.
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Peregrin I; Mendizabal E; Ortiz-Quintana L
Int J Gynecol Cancer; 2015 Jan; 25(1):49-54. PubMed ID: 25405578
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study.
Bagnoli M; Canevari S; Califano D; Losito S; Maio MD; Raspagliesi F; Carcangiu ML; Toffoli G; Cecchin E; Sorio R; Canzonieri V; Russo D; Scognamiglio G; Chiappetta G; Baldassarre G; Lorusso D; Scambia G; Zannoni GF; Savarese A; Carosi M; Scollo P; Breda E; Murgia V; Perrone F; Pignata S; De Cecco L; Mezzanzanica D;
Lancet Oncol; 2016 Aug; 17(8):1137-1146. PubMed ID: 27402147
[TBL] [Abstract][Full Text] [Related]
9. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
Kennedy AW; Hart WR
Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
[TBL] [Abstract][Full Text] [Related]
10. Serous ovarian and primary peritoneal cancers: A comparative analysis of clinico-pathological features, molecular subtypes and treatment outcome.
Gao B; Lindemann K; Anderson L; Fereday S; Hung J; Alsop K; Tothill RW; Gebski V; Kennedy C; Balleine RL; ; Harnett PR; Bowtell DD; DeFazio A
Gynecol Oncol; 2016 Sep; 142(3):458-64. PubMed ID: 27444035
[TBL] [Abstract][Full Text] [Related]
11. [Current FIGO staging classification for cancer of ovary, fallopian tube and peritoneum].
Šišovská I; Minář L; Felsinger M; Anton M; Bednaříková M; Hausnerová J; Jandáková E; Weinberger V
Ceska Gynekol; 2017; 82(3):230-236. PubMed ID: 28593778
[TBL] [Abstract][Full Text] [Related]
12. Survival differences in women with serous tubal, ovarian, peritoneal, and uterine carcinomas.
Usach I; Blansit K; Chen LM; Ueda S; Brooks R; Kapp DS; Chan JK
Am J Obstet Gynecol; 2015 Feb; 212(2):188.e1-6. PubMed ID: 25149685
[TBL] [Abstract][Full Text] [Related]
13. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer.
McPherson A; Roth A; Laks E; Masud T; Bashashati A; Zhang AW; Ha G; Biele J; Yap D; Wan A; Prentice LM; Khattra J; Smith MA; Nielsen CB; Mullaly SC; Kalloger S; Karnezis A; Shumansky K; Siu C; Rosner J; Chan HL; Ho J; Melnyk N; Senz J; Yang W; Moore R; Mungall AJ; Marra MA; Bouchard-Côté A; Gilks CB; Huntsman DG; McAlpine JN; Aparicio S; Shah SP
Nat Genet; 2016 Jul; 48(7):758-67. PubMed ID: 27182968
[TBL] [Abstract][Full Text] [Related]
14. Cancer of the ovary, fallopian tube, and peritoneum.
Berek JS; Kehoe ST; Kumar L; Friedlander M
Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():59-78. PubMed ID: 30306591
[TBL] [Abstract][Full Text] [Related]
15. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
16. The effect of the peritoneal tumor microenvironment on invasion of peritoneal metastases of high-grade serous ovarian cancer and the impact of NEOADJUVANT chemotherapy.
van Baal JOAM; Lok CAR; Jordanova ES; Horlings H; van Driel WJ; Amant FC; Van de Vijver KK
Virchows Arch; 2020 Oct; 477(4):535-544. PubMed ID: 32179982
[TBL] [Abstract][Full Text] [Related]
17. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy.
Esselen KM; Rodriguez N; Growdon W; Krasner C; Horowitz NS; Campos S
Gynecol Oncol; 2012 Oct; 127(1):51-4. PubMed ID: 22659193
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
19. Transketolase is upregulated in metastatic peritoneal implants and promotes ovarian cancer cell proliferation.
Ricciardelli C; Lokman NA; Cheruvu S; Tan IA; Ween MP; Pyragius CE; Ruszkiewicz A; Hoffmann P; Oehler MK
Clin Exp Metastasis; 2015 Jun; 32(5):441-55. PubMed ID: 25895698
[TBL] [Abstract][Full Text] [Related]
20. Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma.
Davidson B; Zhang Z; Kleinberg L; Li M; Flørenes VA; Wang TL; Shih IeM
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):5944-50. PubMed ID: 17062665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
